Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease

Bone Marrow Transplantation

Volumn 36, Issue 4, 2005, Pages 337-341

  Giaccone, L ^a,b   Martin, P ^a,c   Carpenter, P ^a,c   Moravec, C ^a   Hooper, H ^a   Funke, V A M ^a,d   Storb, R ^a,c   Flowers, M E D ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Chronic graft versus host disease; Hematopoietic cell transplantation; Methotrexate

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; FOLIC ACID; GLUCOCORTICOID; HEMOPOIETIC GROWTH FACTOR; MACROLIDE; METHOTREXATE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FASCIITIS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCLERODERMA; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; AGED; CHRONIC DISEASE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 23944454392     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705022     Document Type: Article

References (20)

1. Goerner M, Gooley T, Flowers MED et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8: 47-56.
2. Lee SJ, Volgelsang G, Gilman A et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002; 8: 32-39.
3. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
4. Cutolo M, Bisso A, Sulli A et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2551-2557.
5. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-2682.
6. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases (Review). Arthritis Res 2002; 4: 266-273.
7. Kremer JM, Galivan J, Streckfass A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832-835.
8. Schnabel A. Methotrexate: mechanism of action, pharmacology and toxicology. In: Fellermann K, Jevell DP, Sandborn WJ et al (eds). Immunosuppression in Inflammatory Bowel Diseases. Standards, New Developments, Future Trends. Kluwer Academic Publishers: Dordrecht, 2001, pp 113-118.
9. Schröder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions (Review). Am J Gastroenterol 2003; 98: 530-537.
10. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-822.
11. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 1627-1632.
12. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-210.
13. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation (Review). Arch Intern Med 2000; 160: 610-619.
14. Flowers MED, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells vs bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
15. Flowers MED, Deeg HJ. Delayed complications after hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing Ltd: Oxford, UK, 2004, pp 944-961.
16. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
17. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-841.
18. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
19. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
20. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.